por Pall Biotech 31 de agosto, 2018 Reportajes comentarios Bookmark and Share
< Volver

Continuous bioprocessing initiatives have accelerated in recent years. The transition from batch to continuous bioprocessing offers numerous advantages, including process time savings and lower capital costs due to smaller equipment, tanks, and tubing sizes. Additionally, hold tanks may no longer be needed between unit operations, which can be especially valuable for facilities with limited manufacturing floor space. Furthermore, reduced system hold-up volumes improve product recoveries and also contribute to the smaller system footprint of continuous bioprocessing systems.

Continuous bioprocessing solutions were initially developed for upstream processes (i.e. perfusion bioreactors), but continuous downstream unit operations have recently progressed as well. One unit of operation that is especially beneficial for continuous bioprocessing initiatives is the ultrafiltration (UF) step, which can be accomplished through the use of Pall’s patented single-pass tangential flow filtration (SPTFF) technology [1,2,3,4]. SPTFF eliminates the conventional TFF recirculation loop and utilizes a staged flow path design, allowing concentrations of 2 to 30X to be achieved continuously in a single-pass through the module. The single pump pass reduces minimum working volume concerns and is ideal for processing of fragile biomolecules.


Noticias relacionadas

comments powered by Disqus